Altamira Therapeutics Ltd. Nonderivative Financial Liabilities Undiscounted Cash Flows
Altamira Therapeutics Ltd. (CYTOF) had Nonderivative Financial Liabilities Undiscounted Cash Flows of CHF 5.32 million as of 2021-12-31, per its 20-F filed 2022-04-12.
Discontinued › Notes
ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows · last filed 2022-04-12
- 2021-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 5.32M CHF.
- 2020-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 3.04M CHF.
- 2019-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 2.28M CHF.
- 2018-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 5.24M CHF.
| Period end | Nonderivative Financial Liabilities Undiscounted Cash Flows |
|---|---|
| 2021-12-31 | 5.32M CHF 20-F · filed 2022-04-12 |
| 2020-12-31 | 3.04M CHF 20-F · filed 2022-04-12 |
| 2019-12-31 | 2.28M CHF 20-F · filed 2021-03-31 |
| 2018-12-31 | 5.24M CHF 20-F · filed 2020-04-16 |
| 2017-12-31 | 19.40M CHF 20-F · filed 2019-03-14 |
| 2016-12-31 | 22.48M CHF 20-F · filed 2018-03-22 |